Document:

<PAGE>

                                MERGER AGREEMENT

         This Agreement and Plan of Merger ("Agreement") is entered into by and
among NUELECTRIC, Inc., a Delaware corporation ("NUELECTRIC"), Zorax, Inc., a
Florida corporation ("ZORAX"), and UTEK Corporation, a Delaware corporation
("UTEK").

         WHEREAS, UTEK is the majority shareholder of ZORAX; and

         WHEREAS, ZORAX has the exclusive license to manufacture and market
products using the Cryptosporidium and Giardia extraction processes
("Invention") invented by Dr. C. J. Shiff and T. K. Graczyk and covered by the
patent application pending US Serial # 09/006,999 ("Patent Application") listed
in Exhibit A; and

         WHEREAS, ZORAX has executed and fully funded a Sponsored Research
Agreement (Sponsored Research) with the John Hopkins University (UNIVERSITY)
listed in Exhibit B; and

         WHEREAS, the parties desire to provide for the terms and conditions
upon which ZORAX will merge into NUELECTRIC in a statutory merger ("Merger") in
accordance with Corporation Law of Florida ("Florida Act")and Corporation Law of
Delaware ("Delaware Act"), upon consummation of which the assets and business of
ZORAX will be owned by NUELECTRIC, and all issued and outstanding shares of
capital stock of ZORAX will be exchanged for common stock of NUELECTRIC; and

         WHEREAS, for federal income tax purposes, it is intended that the
Merger qualify as a tax-free reorganization within the meaning of Section 368
(a)(1)(A) of the Internal Revenue Code of 1986, as amended ("Code").

         NOW, THEREFORE, in consideration of the premises and for other good and
valuable consideration, the receipt, adequacy and sufficiency of which are
hereby acknowledged, the parties agree as follows:

                                    ARTICLE 1
                                   THE MERGER

         1.01     The Merger

         (a) Agreement to Merge. Subject to the terms and conditions of this
Agreement, at the Effective Time, as defined below, ZORAX shall be merged with
and into NUELECTRIC in accordance with the provisions of this Agreement and the
Florida Act and Delaware Act; the separate corporate existence of ZORAX shall
cease; and NUELECTRIC shall continue as the surviving corporation ("Surviving
Corporation"). The constituent corporations ("Constituent Corporations") to the
Merger are NUELECTRIC and ZORAX. The name of the Surviving Corporation,
NUELECTRIC, Inc., shall not be changed by reason of the Merger.

                                       1
<PAGE>

         (b) Effective Time. The Merger shall become effective ("Effective Time"
upon the execution of this Agreement. Immediately following the execution of
this Agreement NUELECTRIC will file a Certificate of Merger ("Certificate of
Merger") with the Secretary of State of the State of Florida and State of
Delaware.

         (c) Appointment of Service Agent. NUELECTRIC hereby irrevocably
appoints the Secretary of State of the State of Florida as its agent to accept
process in Florida in any proceeding for the enforcement of any obligation of
any Constituent Corporation in Florida as well as for the enforcement of any
obligation of the Surviving Corporation arising from or by reason of the Merger.
NUELECTRIC designates that all such process received by the Secretary of State
of Florida shall be sent to NUELECTRIC at 624 East Tarpon Avenue, Tarpon
Springs, Florida 34689.

         (d) Effect of the Merger. At the Effective Time, all rights, powers,
privileges, franchises, licenses and permits of the Constituent Corporations and
all property, real, personal and mixed, shall be vested in the Surviving
Corporation; and all debts, duties, liabilities and claims of every kind,
character and description of the Constituent Corporations shall be debts,
duties, liabilities and claims of the Surviving Corporation and may be enforced
against the Surviving Corporation to the same extent as if such debts, duties,
liabilities and claims had been incurred by it originally. All rights of
creditors of the Constituent Corporations and all liens upon property of any
Constituent Corporation shall be preserved unimpaired and shall not be altered
in any way by reason of the Merger.

         1.02     Conversion of Stock. At the Effective Time, by virtue of the
Merger and without any action on the part of the shareholders of the Constituent
Corporations:

         (i) All of the 1,000,000 shares of ZORAX that are issued and
outstanding at the Effective Time shall be converted into 600,000 unregistered
shares of common stock of the Surviving Corporation issued which by agreement of
the shareholders of ZORAX shall be issued to UTEK and to Johns Hopkins
University as they mutually agree; and

         (ii) Each share of common stock of NUELECTRIC issued and outstanding at
the Effective Time shall remain issued and outstanding as one share of common
stock of the Surviving Corporation,

         1.03     Effect of Merger.

         (a) Shareholders Rights in ZORAX Cease. At and after the Effective
Time, the holder of each certificate of common stock of ZORAX shall cease to
have any rights as a shareholder of ZORAX. All dividends or other distributions
with respect to ZORAX common stock prior to the Effective Time shall be payable
to the shareholders of ZORAX without interest upon surrender of certificates
representing ZORAX common stock.

         (b) Closure of ZORAX Stock Records. From and after the Effective Time,
the stock transfer books of ZORAX shall be closed, and there shall be no further
registration of stock transfers on the records of ZORAX.

         1.04     Certificate of Incorporation of the Surviving Corporation. The
certificate of Incorporation of the Surviving Corporation shall not be changed
by reason of the Merger, except that the name of the Surviving Corporation is
being changed to NUELECTRIC, Inc.

                                       2
<PAGE>

         1.05     Bylaws of the Surviving Corporation. The Bylaws of the
Surviving Corporation shall not be changed by reason of the Merger.

         1.06     Directors of the Surviving Corporation. The directors of the
Surviving Corporation immediately after the Effective Time shall be the persons
named in Exhibit B until each of their respective successors is duly elected and
qualified.

         1.07     Officers of the Surviving Corporation. The officers of the
Surviving Corporation immediately after the Effective Time shall be the persons
set forth in Exhibit B until each of their respective successors is duly elected
and qualified.

         1.08     Closing. The Closing of the Merger shall take place at the
offices of Sam Reiber, 601 East Twiggs Street, Suite 200, Tampa, Florida, 33602,
September 21, 2000, or at some other mutually agreed location ("Closing Date").

                                   ARTICLE 11
                         REPRESENTATIONS AND WARRANTIES

         2.01     General Representations and Warranties of UTEK. UTEK
represents and warrants to NUELECTRIC that the facts set forth below are true
and correct:

         (a) Organization. ZORAX is a corporation duly organized, validly
existing and in good standing under the laws of the State of Florida, and that
ZORAX has the requisite power and authority to conduct its business.

         (b) Authorization. The execution of this Agreement and the consummation
of the Merger and the other transactions contemplated hereby have been duly
authorized by the Board of Directors and shareholders of ZORAX; no other
corporate action on its part is necessary in order to execute, deliver,
consummate and perform it obligations hereunder; and ZORAX has all requisite
corporate and other authority to execute and deliver this Agreement and
consummate the transactions contemplated hereby.

         (c) Capitalization. The authorized capital of ZORAX consists of
1,000,000 shares of common stock, par value $.00 per share; at the date hereof,
910,000 shares of common stock were issued and outstanding and owned by UTEK,
and 90,000 shares are owned by Johns Hopkins University and no shares were held
in its treasury. All issued and outstanding shares of common stock of ZORAX have
been duly and validly issued and are fully paid and non-assessable shares and
have not been issued in violation of any preemptive or other rights of any other
person or any applicable laws. There are no outstanding options, warrants,
commitments, calls or other rights or agreements requiring it to issue any
shares of ZORAX common stock or securities convertible into shares of ZORAX's
common stock to anyone for any reason whatsoever.

         (d) Binding Effect. The execution, delivery, performance and
consummation of the Merger and the transactions contemplated hereby will not
violate any obligation to which ZORAX is a party and will not create a default
hereunder; and this Agreement constitutes a legal, valid and binding obligation
of ZORAX, enforceable in accordance with its terms, except as the enforcement
may be limited by bankruptcy, insolvency, moratorium, or similar laws affecting
creditor's rights generally and by the availability of injunctive relief,
specific performance or other equitable remedies.

                                       3
<PAGE>

         (e) Litigation Relating to this Agreement. There are no suits, actions
or proceedings pending or to the knowledge of ZORAX or UTEK threatened which
seek to enjoin the Merger or the transactions contemplated by this Agreement or
which, if adversely decided, would have a materially adverse effect on the
business, results of operations, assets, prospects, the Patent Applications, the
License, or the results of the operations of ZORAX.

         (f) No Conflicting Agreements. Neither the execution and delivery of
this Agreement nor the fulfillment of or compliance by ZORAX with the terms or
provisions hereof will result in a breach of the terms, conditions or provisions
of, or constitute a default under, or result in a violation of, ZORAX's
corporate charter or bylaws, the Patent Applications, the License (as defined
below) or any agreement, contract, instrument, order, judgment or decree to
which ZORAX is a party or by which ZORAX or any of its assets is bound, or
violate any provision of any applicable law, rule or regulation or any order,
decree, writ or injunction of any court or government entity which materially
affects its assets or business.

         (g) Consents. No consent from or approval of any court, governmental
entity or any other person is necessary in connection with execution and
delivery of this Agreement by ZORAX or performance of the obligations of ZORAX
hereunder or under any other agreement to which ZORAX is a party; and the
consummation of the transactions contemplated by this Agreement will not require
the approval of any entity or person in order to prevent the termination of the
Patent Applications, the License, or any other material right, privilege,
license or agreement relating to ZORAX or its assets or business.

         (h) Title to Assets. ZORAX has has good and marketable title to its
assets (tangible and intangible), free and clear of all liens, claims, charges,
mortgages, options, restrictions, security agreements and other encumbrances of
every kind or nature whatsoever.

         (i)      The Patent Applications and the License.

                  (1) To the knowledge of UTEK and ZORAX; the Patent Application
         which is pending is being prosecuted in good faith with diligence.

                  (2) The Invention is owned by Johns Hopkins University, a
         Corporation of the State of Maryland ("UNIVERSITY"). The UNIVERSITY has
         all right, power, authority and ownership and entitlement to file,
         prosecute and maintain in effect the Patents and Patent Applications
         with respect to the Invention listed in Exhibit C hereto; and

                  (3) Dr. C. J. Shiff and T. K. Graczyk are the only Inventors
         of the Invention; and have assigned all their rights in the Invention
         to UNIVERSITY; and

                                       4
<PAGE>

                  (4) The Exclusive License Agreement ("License") date March 28,
         2000 a final copy has been provided to NuELECTRIC by and between ZORAX
         and the Foundation, covering the Invention when executed will be legal,
         valid, binding and enforceable in accordance with its terms; and

                  (5) All of the tangible assets of ZORAX have been operated in
         accordance with customary operating practices generally acceptable in
         its industry to which and have been maintained and are in good working
         order and repair in the ordinary course of business, subject only to
         reasonable and ordinary wear and tear; and

         (j) Liabilities of ZORAX. ZORAX has no assets, no liabilities of any
kind, character or description except those created by the License and Sponsored
Research Agreements with UNIVERSITY, final copies of which have been provided to
NUELECTRIC (Exhibit B).

         (k) Financial Statements. The unaudited financial statements of ZORAX
attached as (Exhibit C) present fairly its financial position and the results of
its operations on the dates and for the periods shown therein; provided,
however, that interim financial statements are subject to customary year-end
adjustments and accruals that, in the aggregate, will not have a material
adverse effect on the overall financial condition or results of its operations.
ZORAX has not engaged in any business not reflected in its financial statements.
There have been no material adverse changes in the nature of its business,
prospects, the value of assets or the financial condition since the date of its
financial statements. There are no outstanding obligations or liabilities of
ZORAX except as specifically set forth in the ZORAX financial statements and
Licensing and Sponsored Research Agreements with UNIVERSITY.

         (l) Taxes. All returns, reports, statements and other similar filings
required to be filed by ZORAX with respect to any federal, state, local or
foreign taxes, assessments, interests, penalties, deficiencies, fees and other
governmental charges or impositions have been timely filed with the appropriate
governmental agencies in all jurisdictions in which such tax returns are
required to be filed; all such tax returns properly reflect all liabilities of
ZORAX for taxes for the periods, property or events covered thereby; and all
taxes, whether or not reflected on those tax returns, and all taxes claimed to
be due from ZORAX by any taxing authority, have been properly paid, except to
the extent reflected on Schedule 2.01(m) where ZORAX has contested in good faith
by appropriate proceedings and reserves have been established on its financial
statements to the full extent if the contest is adversely decided against it.
ZORAX has not received any notice of assessment or proposed assessment in
connection with any tax returns, ZORAX has not extended or waived the
application of any statute of limitations of any jurisdiction regarding the
assessment or collection of any taxes. There are no tax liens (other than any
lien which arises by operation of law for current taxes not yet due and payable)
on any of its assets. There is no basis for any additional assessment of taxes,
interest or penalties. ZORAX has made all deposits required by law to be made
with respect to employees' withholding and other employment taxes, including
without limitation the portion of such deposits relating to taxes imposed upon
ZORAX.

                                       5
<PAGE>

         (m) Absence of Certain Changes or Events. ZORAX has not, and without
the written consent of NUELECTRIC, it will not have:

                  (i) Sold, encumbered, assigned or transferred any of its
                  material assets or its interest in the Patent Applications,
                  the License or any other material asset; or

                  (ii) Amended or terminated the License; or

                  (iii) Suffered any material damage, destruction or loss; or

                  (iv) Made any commitments or agreements for capital
                  expenditures or otherwise; or

                  (v) Entered into any transaction or made any commitment not
                  disclosed to NUELECTRIC; or

         (n) Material Contracts. A complete and accurate copy of all material
agreements, contracts and commitments of the following types, whether written or
oral to which it is a party or is bound, has been provided to NUELECTRIC and
such agreements are in full force and effect without amendment. In addition:

                  (i) There are no outstanding unpaid promissory notes,
                  mortgages, indentures, deed of trust, security agreements and
                  other agreements and instruments relating to the borrowing of
                  money by or any extension of credit to ZORAX; and

                  (ii) There are no outstanding operating agreements, lease
                  agreements or similar agreements by which ZORAX is bound; and

                  (iii) The complete final drafts of the License Agreement, and
                  the Patent Applications and Sponsored Research Agreement with
                  all schedules, exhibits and amendments relating thereto have
                  been provided to NUELECTRIC; and

                  (iv) There are no outstanding licenses to or from others of
                  any intellectual property and trade names; and

                  (v) There are not outstanding contracts or commitments to
                  sell, lease or otherwise dispose of any of ZORAX's property;
                  and

         (o) Compliance with Laws. ZORAX is in compliance with all applicable
laws, rules, regulations and orders promulgated by any federal, state or local
government body or agency relating to its business and operations. ZORAX owns
all franchises, licenses, permits, easements, rights, applications, filings,
registration and other authorizations which are necessary for it to conduct
business, all of which are valid and in full force and effect and ZORAX is in
full compliance therewith.

         (p) Litigation. There is no suit, action or any arbitration,
administrative, legal or other proceeding of any kind or character, or any
governmental investigation pending or threatened against ZORAX or the Patents,
the Patent Applications, the License or the Research Agreement affecting its
assets or business. There are no pending or threatened actions or proceedings
before any court, arbitrator or administrative agency which would, if adversely
determined, individually or in the aggregate, materially and adversely affect
its assets or business.

                                       6
<PAGE>

         (q) Employees. ZORAX has no employees. ZORAX is not a party to or bound
by any employment agreement or any collective bargaining agreement with respect
to any of the employees.

         (r) Employee Benefit Plans. There are no employee benefit plans in
effect, and there are no outstanding or unfunded liabilities to employees of
ZORAX.

         (s) Books and Records. The books and records of ZORAX are complete and
accurate in all material respects, fairly present its business and operations,
have been maintained in accordance with good business practices, and accurately
reflect in all material respects its business, financial condition and
liabilities.

         (t) No Broker's Fees. Neither UTEK nor ZORAX has incurred any finder's,
broker's, investment banking, financial, advisory or other similar fees or
obligations.

         (u) Full Disclosure. All representations or warranties of UTEK and
ZORAX are true, correct and complete in all material respects to the best of our
knowledge on the date hereof and shall be true, correct and complete in all
material respects as of the Closing as if they were made on such date.

         2.02     General Representations and Warranties of NUELECTRIC.
NUELECTRIC represents and warrants to UTEK and ZORAX that the facts set forth
are true and correct.

         (a) Organization. NUELECTRIC is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware, is
qualified to do business as a foreign corporation in each other jurisdiction in
which the conduct of its business or the ownership of its properties require
such qualification, and has all requisite power and authority to conduct its
business and operate properties.

         (b) Authorization. The execution of this Agreement and the consummation
of the Merger and the other transactions contemplated hereby have been duly
authorized by the Board of Directors and shareholders of NUELECTRIC; no other
corporate action on its part is necessary in order to execute, deliver,
consummate and perform its obligations hereunder; and it has all requisite
corporate and other authority to execute and deliver this Agreement and
consummate the transactions contemplated hereby.

         (c) Capitalization. The authorized capital of NUELECTRIC consists of
50,000,000 shares of common stock, par value $.001 per share; and at the
Effective Time of the Merger, up to 4,712,855 shares of its common stock will be
issued and outstanding immediately after the Effective Time. All issued and
outstanding shares of common stock of NUELECTRIC have been duly and validly
issued and are fully paid and non-assessable shares and have not been issued in
violation of any preemptive or other rights of any other person or any
applicable laws. There will be no outstanding options, warrants, commitments,
calls or other rights or agreements requiring it to issue any shares of
NUELECTRIC common stock or securities convertible into shares of its common
stock to anyone for any reason whatsoever immediately after the Effective Time.

                                       7
<PAGE>

         (d) Binding Effect. The execution, delivery, performance and
consummation of the Merger and the transactions contemplated hereby will not
violate any obligation to which NUELECTRIC is a party and will not create a
default hereunder, and this Agreement constitutes a legal, valid and binding
obligation of NUELECTRIC, enforceable in accordance with its terms, except as
the enforcement may be limited by bankruptcy, insolvency, moratorium, or similar
laws affecting creditor's rights generally and by the availability of injunctive
relief, specific performance or other equitable remedies.

         (e) Litigation Relating to this Agreement. There are no suits, actions
or proceedings pending or to its knowledge threatened which seek to enjoin the
Merger or the transactions contemplated by this Agreement or which, if adversely
decided, would have a materially adverse effect on its business, results of
operations, assets, prospects or the results of its operations of NUELECTRIC.

         (f) No Conflicting Agreements. Neither the execution and delivery of
this Agreement nor the fulfillment of or compliance by NUELECTRIC with the terms
or provisions thereof will result in a breach of the terms, conditions or
provisions of, or constitute a default under, or result in a violation of, its
corporate charter or bylaws, or any agreement, contract, instrument, order,
judgment or decree to which it is a party or by which it or any of the assets is
bound, or violate any provision of any applicable law, rule or regulation or any
order, decree, writ or injunction of any court or governmental entity which
materially affects its assets or business.

         (g) Consents. No consent from or approval of any court, governmental
entity or any other person is necessary in connection with its execution and
delivery of this Agreement and performance of the obligations of NUELECTRIC
hereunder or under any other agreement to which NUELECTRIC is a party; and the
consummation of the transactions contemplated by this Agreement will not require
the approval of any entity or person in order to prevent the termination of any
material right, privilege, license or agreement relating to NUELECTRIC or its
assets or business.

         (h) Title to Its Assets. NUELECTRIC has good and marketable title to
its assess (tangible and intangible), free and clear of all charges, claims,
liens, mortgages, options, restrictions, security agreements and other
encumbrances of every kind or nature whatsoever.

         (i) Condition of Tangible Assets. All of its tangible assets have been
operated in accordance with customary operating practices generally acceptable
in its industry to which and have been maintained and are in good working order
and repair in the ordinary course of business, subject only to reasonable and
ordinary wear and tear.

         (j) Financial Statements. The unaudited financial statements of
NUELECTRIC attached as Exhibit D present fairly its financial position and the
results of its operations on the dates and for the periods shown therein;
provided, however, that interim financial statements are subject to customary
year-end adjustments and accruals that, in the aggregate, will not have a
material adverse effect on the overall financial condition or results of its
operations. NUELECTRIC has not engaged in any business not reflected in its
financial statements. There have been no material adverse changes in the nature
of its business, prospects, the value of assets or the financial condition since
the date of its financial statements. There are no outstanding obligations or
liabilities of NUELECTRIC except as specifically set forth in the NUELECTRIC
financial statements.

                                       8
<PAGE>

         (k) Taxes. All returns, reports, statements and other similar filings
required to be filed by NUELECTRIC with respect to any federal, state, local or
foreign taxes, assessments, interests, penalties, deficiencies, fees and other
governmental charges or impositions have been timely filed with the appropriate
governmental agencies in all jurisdictions in which such tax returns are
required to be filed; all such tax returns properly reflect all liabilities of
NUELECTRIC for taxes for the periods, property or events covered thereby; and
all taxes, whether or not reflected on those tax returns, and all taxes claimed
to be due from NUELECTRIC by any taxing authority, have been properly paid,
except to the extent reflected in Exhibit E where NUELECTRIC has contested in
good faith by appropriate proceedings and reserves have been established on its
financial statements to the full extent if the contest is adversely decided
against it. NUELECTRIC has not received any notice of assessment or proposed
assessment in connection with any tax returns, NUELECTRIC has not extended or
waived the application of any statute of limitations of any jurisdiction
regarding the assessment or collection of any taxes. There are no tax liens
(other than any lien which arises by operation of law for current taxes not yet
due and payable) on any of its assets. There is no basis for any additional
assessment of taxes, interest or penalties. NUELECTRIC has made all deposits
required by law to be made with respect to employees' withholding and other
employment taxes, including without limitation the portion of such deposits
relating to taxes imposed upon NUELECTRIC.

         (l) Absence of Certain Changes or Events. NUELECTRIC has not and,
without the written consent of ZORAX, it will not have:

                  (i) Sold, encumbered, assigned or transferred any of its
                  material assets for less than fair consideration; or

                  (ii) Amended or terminated any material agreement; or

                  (iii) Suffered any material damage, destruction or loss; or

                  (iv) Received notice or had knowledge of any material adverse
                  effect on its material assets; or

                  (v) Made any commitments or agreements for capital
                  expenditures; or

                  (vi) Entered into any transaction other than in the ordinary
                  course of business consistent with past practice; or

                  (vii) Agreed to take any of the actions set forth in this
                  paragraph.

         (m) Material Contracts. A complete and accurate copy of all material
agreements, contracts and commitments of the following types, whether written or
oral to which it is a party or is bound, has been provided to ZORAX:

                                       9
<PAGE>

                  (i) All material promissory notes, mortgages, indentures, deed
                  of trust security agreements and other agreements and
                  instruments relating to the borrowing of money by or any
                  extension of credit to it; and

                  (ii) All material operating agreements and lease agreements;
                  and

                  (iii) All material licenses to or from others of any
                  intellectual property and trade names.

         (n) Compliance with Laws. NUELECTRIC is in compliance with all
applicable laws, rules, regulations and orders promulgated by any federal, state
or local governmental body or agency relating to its business and operations.
NUELECTRIC owns all franchises, licenses, permits, easements, rights,
applications, filings, registration and other authorizations which are necessary
for it to conduct business, all of which are valid and in full force and effect,
and it is in full compliance therewith.

         (o) Litigation. There is no suit, action or any arbitration,
administrative, legal or other proceeding of any kind or character, or any
governmental investigation pending or threatened against it affecting its assets
or business. There are no pending or threatened actions or proceedings before
any court, arbitrator or administrative agency which would, if adversely
determined, individually or in the aggregate, materially and adversely affect
its assets or business.

         (p) Employees. NUELECTRIC has three employees. NUELECTRIC has no
written agreements with its employees.

         (q) Employee Benefit Plans and Arrangements. There are no employee
benefit plans in effect, and there are no unfunded liabilities to employees.

         (r) Books and Records. The books and records of NUELECTRIC are complete
and accurate in all material respects, fairly present its business and
operations, have been maintained in accordance with good business practices, and
accurately reflect in all material respects its business and financial
condition.

         (s) No Broker's Fees. NUELECTRIC has incurred no finder's, broker's,
investment banking, financial, advisory or other similar fee.

         (t) Full Disclosure. All representations or warranties of NUELECTRIC
are true, correct and complete in all material respects on the date hereof and
shall be true, correct and complete in all material respects as of the Closing
as if they were made on such date. No statement made by it herein or in the
exhibits hereto or any document delivered by it or on its behalf pursuant to
this Agreement contains an untrue statement of material fact or omits to state
all material facts necessary to make the statements therein not misleading in
any material respect.

         2.03.    Investment Representations of UTEK. UTEK represents and
warrants to NUELECTRIC that:

                                       10
<PAGE>

         (a) General. It has such knowledge and experience in financial and
business matters as to be capable of evaluating the risks and merits of an
investment in the shares ("Shares") of common stock of NUELECTRIC pursuant to
the Merger. It is able to bear the economic risk of the investment in the
Shares, including the risk of a total loss of the investment in the Shares. The
acquisition of the Shares is for its own account and is for investment. Except a
permitted by law, it has a no present intention of selling, transferring or
otherwise disposing in any way of all or any portion of the shares. All
information that it has supplied to NUELECTRIC is true and correct. It has
conducted all investigations and due diligence concerning NUELECTRIC which it
deems appropriate, and it has found all such information obtained fully
acceptable. It has had an opportunity to ask questions of the officer and
directors of NUELECTRIC concerning the Shares and the business and financial
condition of and prospects for NUELECTRIC, and the officers and directors
NUELECTRIC have adequately answered all questions asked and made all relevant
information available to them.

         (b) Stock Transfer Restrictions. There will be a 24-month stock
transfer restrictions on the shares issued by NUELECTRIC in connection with this
Agreement.

                                   ARTICLE III
                          TRANSACTIONS PRIOR TO CLOSING

         3.01. Corporate Approvals. Prior to Closing, each of the parties shall
submit this Agreement to its Board of Directors and shareholders and obtain
approval thereof. Copies of corporate actions taken shall be provided to each
party.

         3.02 Access to Information. Each party agrees to permit upon reasonable
notice the attorneys, accountants, and other representatives of the other
parties reasonable access during normal business hours to its properties and its
books and records to make reasonable investigations with respect to its affairs,
and to make its officers and employees available to answer questions and provide
additional information as reasonably requested.

         3.03 Expenses. Each party agrees to bear its own expenses in connection
with the negotiation and consummation of the Merger and the transactions
contemplated hereby.

         3.04 Covenants. Except as permitted in writing, each party agrees that
it will:

                  (i) Use its good faith efforts to obtain all requisite
                  licenses, permits, consents, approvals and authorizations
                  necessary in order to consummate the Merger; and

                  (ii) Notify the other parties upon the occurrence of any event
                  which would have a materially adverse effect upon the Merger
                  or the transactions contemplated hereby or upon the business,
                  assets or results of operations; and

                  (iii) Not modify its corporate structure, except as necessary
                  or advisable in order to consummate the Merger and the
                  transactions contemplated hereby.

                                       11
<PAGE>

                                   ARTICLE IV
                              CONDITIONS PRECEDENT

         The obligation of the parties to consummate the Merger and the
transactions contemplated hereby are subject to the following conditions which
may be waived to the extent permitted by law:

         (a) Each party must obtain the approval of its Board of Directors and
shareholders in accordance with applicable law, and such approval shall not have
been rescinded or restricted; and

         (b) Each party shall obtain all requisite licenses, permits, consents,
authorizations and approvals required to complete the Merger and the
transactions contemplated hereby; and

         (c) There shall be no effective injunction, writ or preliminary
restraining order or other order of a similar nature issued by any court or
governmental agency having jurisdiction directing that the Merger or the
transactions contemplated hereby shall not be consummated; and

         (d) The representations and warranties of the parties shall be true and
correct in all material respects at the Effective Time; and

         (e) The Patent Applications have been prosecuted in good faith with
reasonable diligence.

         (f) The License Agreement is valid and in full force and effect without
any default therein.

                                    ARTICLE V
                                 INDEMNIFICATION

         (a) By UTEK. UTEK agrees to indemnify, defend and hold harmless
NUELECTRIC and its shareholders, directors, officers, employees, agents and
representatives and their respective successors and assigns against and in
respect of any cost, damage, expense (including reasonable legal fees and actual
expenses), liability or loss incurred or suffered by any of them resulting from
or arising out of the (I) breach, inaccuracy, misrepresentation or untruth of
any representation or warranty, or the nonfulfillment of any agreement or
covenant of UTEK contained in this Agreement or in any document delivered by
UTEK or ZORAX to NUELECTRIC pursuant hereto; and (ii) any action, assessment,
claim, demand, proceeding or suit incident to any of the foregoing. The
liability of UTEK hereunder shall be satisfied by the return to NUELECTRIC of
shares of NUELECTRIC common stock issued pursuant hereto.

         (b) By NUELECTRIC. NUELECTRIC agrees to indemnify, defend and hold
harmless UTEK and its shareholders, officers, directors, employees, agents and
representatives and their respective successors and assigns against and in
respect of any cost, damage, expense (including reasonable legal fees and actual
expenses), liability or loss incurred or suffered by any of them resulting from
or arising out of: (I) the breach, inaccuracy, misrepresentation or untruth of
any representation, warranty, or the nonfulfillment of any agreement or covenant
of NUELECTRIC contained in this Agreement or in any document delivered by it to
UTEK pursuant hereto; and (ii) any action, assessment, claim, demand, proceeding
or suit incident to any of the foregoing.

                                       12
<PAGE>

         (c) Costs. The indemnification rights and obligations of a party hereto
shall include the right to receive and the duty to pay and reimburse the
indemnified party all its reasonable costs and expenses incurred in the
enforcement of its rights hereunder.

         (d) Survival of Representations and Warranties.

                  (1) The representations and warranties made by UTEK shall
         survive for a period of one year after Closing, and thereafter all such
         representation and warranties shall be extinguished, except with
         respect to claims then pending for which specific notice has been given
         during such one year period. UTEK shall have liability and
         responsibility for the surviving representations and warranties made by
         it herein, notwithstanding any due diligence investigation or
         examination by NUELECTRIC.

                  (2) The representations and warranties made by NUELECTRIC
         shall survive for a period of one year after Closing, and thereafter
         all such representations and warranties shall be extinguished, except
         with respect to claims then pending for which specific notice has been
         given during such one year period. NUELECTRIC shall have liability and
         responsibility for the surviving representations and warranties made to
         NUELECTRIC, notwithstanding any due diligence investigation or
         examination by UTEK.

         (e) Limitations on Liability. Notwithstanding any other provision
herein to the contrary, neither party hereto shall be liable to the other party
for any cost, damage, expense, liability or loss under this indemnification
provision until after the sum of all amounts individually when added to all
other such amounts in the aggregate exceeds $500, and then such liability shall
apply only to matters in excess of $500.

         (f) Rights of Indemnitors. The indemnified party shall notify the
indemnifying party of the assertion of commencement of such action, claim or
proceeding within a reasonable period of time or, if citation or service of
process has been made, within 15 days thereafter. The indemnified party may, at
its option and at its sole expense, participate in the defense of and contest
any such action, claim or proceeding; provided, however, the indemnified party
shall at all times also have the right to participate fully therein. If the
indemnifying party, within a reasonable time after receiving such notice, fails
to participate, the indemnified party shall have the right, but shall not be
obligated, to undertake the defense of the action, claim or proceeding for the
account of and at the risk of the indemnifying party; provided, however, in the
event that the indemnified party shall determine to compromise or settle
(exercising its judgment in good faith) any such action, claim or proceeding,
the indemnified party shall be required to give the indemnifying party 15 days'
notice of such determination after it receipt of actual notice of the claim. The
indemnified party shall then be entitled to compromise or settle the action,
claim, or proceeding for the account of and at the risk of the indemnifying
party; provided, however, the settlement shall be effective without the consent
of both the indemnifying and indemnified parties, which consent shall not be
reasonably withheld. The parties agree that any indemnified party may join any
indemnifying party in any action, claim or proceeding brought by a third part,
as to which any right of indemnity created by this Agreement would or might
apply, for the purpose of enforcing any right of the indemnity granted to such
indemnified party pursuant to this Agreement.

                                       13
<PAGE>

         (g) Additional Rights. Any right of indemnity of any party pursuant to
this Agreement shall be in addition to and shall not operate as a limitation on
any other right to indemnity of such party pursuant to this Agreement, any
document or instrument executed in connection with the consummation of the
transaction contemplated hereby or otherwise.

                                   ARTICLE VI
                                    COVENANT

         NUELECTRIC will promptly provide financial statements to UTEK
Corporation following the end of each fiscal quarter. This covenant will survive
this Merger Agreement and will continue as long as UTEK owns stock in
NUELECTRIC.

                                   ARTICLE VII
                                   ARBITRATION

         In the event a dispute arises with respect to the interpretation or
effect of this Agreement or concerning the rights or obligations of the parties
hereto, the parties agree to negotiate in good faith with reasonable diligence
in an effort to resolve the dispute in a mutually acceptable manner. Failing to
reach a resolution thereof, either party shall have the right to submit the
dispute to be settled by arbitration under the Commercial Rules of Arbitration
of the American Arbitration Association. The parties agree that all arbitration
shall be conducted in Tampa, Florida, unless the parties mutually agree to the
contrary. The cost of arbitration shall be borne by the party against whom the
award is rendered or, if in the interest of fairness, as allocated in accordance
with the judgment of the arbitrators. All awards in arbitration made in good
faith and not infected with fraud or other misconduct shall be final and
binding.

                                  ARTICLE VIII
                                  MISCELLANEOUS

         No party may assign this Agreement or any right or obligation of it
hereunder without the prior written consent of the other parties hereto. No
permitted assignment shall relieve a party of its obligations under this
Agreement without the separate written consent of the other parties. This
Agreement shall be binding upon and enure to the benefit of the parties and
their respective permitted successors and assigns. Each party agrees that it
will comply with all applicable laws, rules and regulations in the execution and
performance of its obligations under this Agreement. This Agreement shall be
governed by and construct in accordance with the laws of the State of Florida.
This document constitutes a complete and entire agreement among the parties with
reference to the subject matters set forth herein. No statement or agreement,
oral or written, made prior to or at the execution hereof and no prior course of
dealing or practice by either party shall vary or modify the terms set forth
herein without the prior consent of the other parties hereto. This Agreement may
be amended only by a written document signed by the parties. Notices or other
communications required to be made in connection with this Agreement shall be
delivered to the parties at the address set forth below or at such other address
as may be changed from time to time by giving written notice to the other
parties. This Agreement may be executed in multiple counterparts, each of which
shall constitute one and a single Agreement.

                                       14
<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Agreement to be duly
executed by a duly authorized officer this 21st day of September 2000.

NUELECTRIC, INC.                            ZORAX, INC.

By:______________________                   By:________________________
   Laurie Scala, President                     Uwe Reischl, President

UTEK Corporation

By:________________________
   Clifford M. Gross
   Chief Executive Officer

                                       15
<PAGE>

                                    Exhibit A

                               Patent Application

                              US Serial #09/006,999
        Apparatus for the Separation of Cystic Parasite Forms from Water

         The following patent application is confidential and should not be
distributed without the prior written consent of Johns Hopkins University.

                                       16
<PAGE>
                                    Exhibit B

          License Agreement Between ZORAX and Johns Hopkins University
  Sponsored Research Agreement Between Zorax, Inc. and Johns Hopkins University

                                       17
<PAGE>

                                    Exhibit C

                          Financial Statement of ZORAX

                                       18
<PAGE>

                                    Exhibit D

                     Financial Statement of NUELECTRIC, Inc.

                                       19<PAGE>   1
                                                                    EXHIBIT 10.1

                                  4 AUGUST 1997

                           AMERSHAM INTERNATIONAL PLC

                       AMERSHAM PHARMACIA BIOTECH LIMITED

                   ==========================================

                            AGREEMENT RELATING TO THE
                          PROVISION OF GENERAL SERVICES

                   ==========================================

                               [FRESHFIELDS LOGO]
<PAGE>   2
                                    CONTENTS

<TABLE>
<CAPTION>
CLAUSE                                                             PAGE
<S>                                                                <C>
INTERPRETATION .............................................         1

SERVICES TO BE PROVIDED ....................................         2

BIOTECH'S OBLIGATIONS ......................................         3

INTERNATIONAL'S OBLIGATIONS ................................         4

CHARGES ....................................................         4

LIABILITY ..................................................         6

FORCE MAJEURE ..............................................         7

DURATION AND TERMINATION ...................................         7

EFFECT OF TERMINATION ......................................         9

NATURE OF AGREEMENT ........................................        10

NOTICES ....................................................        12

TERMS OF REFERENCE FOR DISPUTES ............................        13

ARBITRATION AND GOVERNING LAW ..............................        13

SCHEDULE 1 .................................................        14

      Part A:  SERVICES TO BE PROVIDED BY INTERNATIONAL ....        14

      Part B:  SERVICES TO BE PROVIDED BY AMERSHAM

      HOLDINGS, INC. .......................................        21

SCHEDULE 2 .................................................        26

        SHARED SERVICE TERMINATION .........................        26
</TABLE>
<PAGE>   3
AN AGREEMENT made on 4 August 1997

BETWEEN

AMERSHAM INTERNATIONAL PLC (Company no. 1002610) whose registered office is at
Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA (INTERNATIONAL)

AMERSHAM PHARMACIA BIOTECH LIMITED (Company no. 3366621) whose registered office
is at Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA (BIOTECH)

WHEREAS

(A) Pursuant to the Contribution Agreement dated 10 June 1997, as amended by the
Contribution Amendment Agreement, dated 4 August, 1997 (CONTRIBUTION AGREEMENT),
between International, Pharmacia & Upjohn Inc. (PHARMACIA & UPJOHN) and Biotech,
International and Pharmacia & Upjohn have agreed to merge (the BIOTECH MERGER)
their respective life science businesses to form a new company, Biotech.

(B) Biotech wishes International and certain of its subsidiaries to provide
various services in relation to the Biotech Business (as defined below) and
International is willing to provide the same on the terms and conditions of this
Agreement.

IT IS AGREED as follows:

INTERPRETATION

1.1 The following terms shall, unless the context otherwise requires, have the
following respective meanings:

AM LABS SITE means all that freehold property known as Amersham Laboratories,
White Lion Road, Amersham;

AMERSHAM GROUP means International, any holding company from time to time of
International and any subsidiary of International or of any such holding company
(other than the Biotech Group);

AMERSHAM PARTIES means International and Holdings;

BIOTECH BUSINESS means the business of Biotech, comprising the life science
business of International and the biotechnology business of Pharmacia & Upjohn;

BIOTECH GROUP means Biotech, any holding company from time to time of Biotech
and any subsidiary of Biotech or of any such holding company;

BIOTECH SITES means the sites based at (i) 1st Floor, Amersham Place, Little
Chalfont, Buckinghamshire HP7 9NA, (ii) Units 2A, 2B and 10, St George's, White
Lion Road, Amersham (iii) Pollards Wood, (iv) Mandeville House; (v) 2636 South
Clearbrook Drive, Arlington Heights, Illinois, 60005; (vi) 26111
<PAGE>   4
Miles-Road, Cleveland, Ohio 44128; and (vii) 955 William Pitt Way, Pittsburgh
Pennsylvania 15238.

BUSINESS DAY means any day other than Saturday or Sunday or a Bank or Public
Holiday;

BUSINESS HOURS means the hours of 8.30 a.m. to 5.30 p.m.;

CARDIFF SITE means all that freehold property known as Forest Farm, Whitchurch,
Cardiff;

COMPLETION means completion of the Contribution Agreement in accordance with
clause 6 thereof;

CONTRACT MANUFACTURE AGREEMENTS means the Contract Manufacture and Research and
Development Agreements in the agreed form to be made between International and
Amersham Life Science Limited pursuant to which International agrees to
manufacture certain products and provide certain research and development
services for Amersham Life Science Limited at the Cardiff Site and the Am Labs
Site;

FORCE MAJEURE means in relation to either party, any circumstances beyond the
reasonable control of that party (including, without limitation, any strike,
lockout or similar form of industrial action);

HOLDINGS means Amersham Holdings, Inc. a Delaware company and a wholly owned
subsidiary of International;

INTERNATIONAL YEAR END is, in any one year, 31 December (or such other date as
International may select from time to time);

LIBOR means the arithmetic mean (rounded upward to five decimal places) of the
rates quoted by the principal office in London of Lloyds Bank plc and National
Westminster Bank plc to leading banks in the London Interbank market at or about
11.00 a.m. on the relevant date for the offering of deposits in Sterling for a
one-month period;

SERVICES means the services which are to be provided by the Amersham Parties to
Biotech in accordance with this Agreement set out in Schedule 1.

1.2 References to statutory provisions shall, except where the context requires
otherwise, be construed as references to those provisions as respectively
amended or re-enacted or as their application is modified by other statutory
provisions (whether before or after the date hereof) from time to time.

1.3 Headings are inserted for convenience only and shall not affect the
construction of this Agreement or the Schedules hereto.

SERVICES TO BE PROVIDED

2.1 The Amersham Parties will provide the Services to Biotech on the terms and
conditions set out herein during Business Hours of each Business Day, as and
when requested by Biotech, for so long as this Agreement shall remain in force.
<PAGE>   5
2.2 The Amersham Parties shall use all reasonable endeavours to ensure that the
personnel providing the Services are suitably qualified. In connection with the
provision of Services hereunder, the Amersham Parties will comply in all
material respects with all applicable laws, regulations and safety guidelines of
all governmental entities.

2.3 Save as otherwise specifically agreed herein, the Amersham Parties shall, in
supplying the Services under this Agreement, comply with such practices and
procedures as were followed in respect of the relevant services prior to the
Biotech Merger and will perform the Services in all material respects in the
same manner and with the same level of efficiency as the Services were performed
prior to Completion.

2.4 The Amersham Parties undertake that they each will use reasonable endeavours
to provide the Services in a cost efficient and effective manner.

2.5 Forthwith upon the termination of this Agreement, howsoever caused, the
Amersham Parties shall return or deliver to Biotech all books, records
(including machine readable records) and documents in the possession or control
of the Amersham Parties and which relate to the provision of the Services
hereunder.

BIOTECH'S OBLIGATIONS

3.1 Biotech shall ensure that all relevant personnel of the Amersham Parties
have such access to the Biotech Sites and to any information or records kept by,
or under the control of, Biotech in relation to the Biotech Business as is
necessary to enable the Amersham Parties to provide the Services. In particular,
without prejudice to the generality of the foregoing, Biotech shall ensure that
appropriate payroll data is supplied, as required, to International on a timely
basis each month and to Holdings on a bi-weekly basis.

3.2 Biotech shall take such reasonable steps as may be necessary to ensure the
safety of any of the personnel of the Amersham Parties who visit any of the
Biotech Sites.

3.3 Biotech shall use reasonable endeavours to respond promptly to any requests
for guidance, instruction or information reasonably required by the Amersham
Parties to enable them to provide the Services.

3.4 Biotech shall keep confidential all information concerning the Amersham
Parties (and other members of the Amersham Group) or the Services imparted or
received under or in connection with this Agreement and shall not divulge the
same to any third party without the prior written consent of International.
Should disclosure of any such information be required by law or by any final,
non-appealable judgement of any court of competent jurisdiction, then Biotech
shall be entitled to disclose the same subject only to prior consultation with
International as to the form and content of such disclosure.

3.5 Biotech undertakes to ensure that any stationery (including, without
limitation, cheques, letterhead and invoices) supplied to the Amersham Parties
<PAGE>   6
to enable the Amersham Parties to provide the Services shall be fully compatible
with the systems and equipment maintained by the Amersham Parties.

INTERNATIONAL'S OBLIGATIONS

4.1 The Amersham Parties shall ensure that all relevant Biotech personnel have
such access to any sites operated by the Amersham Parties and to any information
or records kept by, or under the control of, the Amersham Parties in relation
to the Biotech Business as is necessary to enable Biotech to comply with its
obligations in relation to the Services.

4.2 The Amersham Parties shall take such reasonable steps as may be necessary to
ensure the safety of any of the personnel of Biotech who visit any sites
operated by the Amersham Parties.

4.3 The Amersham Parties shall use reasonable endeavours to respond promptly to
any requests for information reasonably required by Biotech in connection with
the provision of Services under this Agreement.

4.4 The Amersham Parties shall keep confidential all information concerning
Biotech (and any other member of the Biotech Group) or the Services imparted or
received under or in connection with this Agreement and shall not divulge the
same to any third party without the prior written consent of Biotech. Should
disclosure of any such information be required by law or by any final,
non-appealable judgement of any court of competent jurisdiction, the Amersham
Parties shall be entitled to disclose the same subject only to the prior
consultation with Biotech as to the form and content of such disclosure.

CHARGES

5.1 For the period between the date of this Agreement and the International Year
End next following the date of this Agreement, the charges for the provision of
the Services shall be calculated using the bases set out in Schedule 1 (as
revised from time to time in accordance with clause 5.5). For the avoidance of
doubt, in no event shall Biotech be obliged to pay an amount in respect of
Services in excess of the cost to the Amersham Parties of providing such
Services and, for this purpose, the cost to the Amersham Parties shall be
determined in accordance with the bases set out in Schedule 1 (provided that
such bases are no less favourable to Biotech than past practice as previously
disclosed to Pharmacia & Upjohn) and generally accepted accounting principles in
the United Kingdom.

5.2 In respect of the period referred to in clause 5.1 and any period between
the end of such period and any subsequent International Year End, subject to
clause 5.3 below, the Amersham Parties will on the first Business Day of each
calendar month within that period deliver to Biotech an invoice for an amount
equal to one twelfth of the estimated annual charge as specified in Schedule 1
(as revised from time to time in accordance with clause 5.5) in respect of each
service then being provided, in each case together with VAT thereon, if
applicable. Within twenty Business Days of delivery thereof, Biotech shall pay
<PAGE>   7
by telegraphic transfer to the accounts from time to time notified to Biotech by
the Amersham Parties the amount specified on such invoice (together with any VAT
thereon, if applicable).

5.3 Within ten Business Days of the last day of each of the four three calendar
month periods ending on an International Year End, the Amersham Parties shall
send to Biotech a statement showing the amount (if any) by which the aggregate
amount of the invoices delivered in such period pursuant to clause 5.2 is either
more or less than the actual aggregate cost of the Services for such quarter
determined in accordance with clause 5.1 and Schedule 1 (as it may be revised
from time to time) and (i) the amount of the excess (if more) shall be deducted
from the next payment due to be made by Biotech to the relevant Amersham Party
under clause 5.2 above (and the amount of the invoice to be delivered by such
Amersham Party shall be reduced accordingly); or (ii) the amount of the
shortfall (if less) shall be added to the next payment due to be made by Biotech
to the relevant Amersham Party under clause 5.2 (and the amount of the invoice
to be delivered by such Amersham Party shall be increased accordingly (including
any VAT thereon, if applicable)).

5.4 If Biotech shall not pay any amount on the due date in accordance with this
Agreement, any amount unpaid shall bear interest at a rate equal to the base
rate from time to time of LIBOR plus 1% from the date of due payment to and
including the date of payment, whether before or after judgement.

5.5 By not later than 30 days prior to the date of each consecutive
International Year End following the date of this Agreement, the Amersham
Parties will produce, and will deliver to Biotech, a revised Schedule 1
containing the estimated charging rates for the provision of the Services for
the following year and the bases for the calculation of such rates.

5.6 Without prejudice to the generality of clause 4.1, in the event that Biotech
and/or Pharmacia & Upjohn disagrees with any statement delivered by the Amersham
Parties pursuant to clause 5.3 or any revision to Schedule 1 made in accordance
with clause 5.5 or any payments to be made pursuant to clause 9.2, the Amersham
Parties shall, upon request, supply Biotech and/or Pharmacia & Upjohn with such
information as is reasonably necessary to support the calculations contained in
such statement. The Amersham Parties shall also permit Biotech to have such
access as it may reasonably request on reasonable notice to the books and
records maintained by the Amersham Parties in connection with the provision of
the Services to enable Biotech to verify such information. The parties shall use
all reasonable endeavours (in conjunction with their respective accountants) to
meet and discuss the basis of the calculations contained in such statement but
if they fail to reach agreement within twenty Business Days of delivery of the
statement, then, unless the parties agree otherwise, the dispute shall be
referred to a partner of an independent internationally recognised firm of
chartered accountants agreed upon by the parties or, failing agreement, to be
selected by the president for the
<PAGE>   8
time being of the Institute of Chartered Accountants in England and Wales. The
terms of reference set out in clause 12 shall apply.

5.7 If, at the request of Biotech, the Amersham Parties provide a service or
services to Biotech which is not specified in Schedule 1, Biotech shall pay to
the Amersham Parties a reasonable sum for such service or services.

LIABILITY

6.1 Without prejudice to any other limitation or exclusion of liability under
this Agreement (and without prejudice to the rights of either party to sue the
other for damages for breach of this Agreement):

(a)   the Amersham Parties shall not be liable to Biotech for any loss of
      profits or other indirect or consequential loss of any kind, as a result
      of the provision of the Services (excluding, for the avoidance of doubt,
      any loss or liability arising from death or personal injury due to the
      negligence of the Amersham Parties);

(b)   the total liability of the Amersham Parties to Biotech in respect of any
      one event, or series of connected events, shall not exceed the total
      charges paid by Biotech to the Amersham Parties for the Services in the
      twelve month period prior to the occurrence of such event or series of
      events less any amount already paid in that period to Biotech by the
      Amersham Parties under any warranty, indemnity or other obligation under
      this Agreement or in respect of any breach of this Agreement.

6.2 Subject to clause 6.1 and to clause 7, Amersham Parties will indemnify
Biotech and hold it harmless from and against any claim or action (including
reasonable litigation costs and expenses including reasonable legal fees)
brought by any third party against Biotech arising from any negligent or
reckless act or omission on the part of the Amersham Parties or any of the
personnel of the Amersham Parties.

6.3 Biotech will indemnify the Amersham Parties for any loss or damage
(including reasonable litigation costs and expenses including reasonable legal
fees) which the Amersham Parties suffer as a result of any claim or action
brought by a third party against the Amersham Parties in respect of any Services
provided by the Amersham Parties hereunder, which claim or action has not arisen
from any negligent or reckless act or omission on the part of the Amersham
Parties or any of the personnel of the Amersham Parties.

6.4 For the avoidance of doubt, the Amersham Parties shall have no liability to
Biotech in respect of or arising out of the performance, or non-performance, of
the Services save as expressly set out in this Agreement.

6.5 In particular, without prejudice to the generality of the foregoing, Biotech
hereby confirms and acknowledges that:

(a)   it undertakes to check and verify any accounts and supporting schedules
      prepared by International; and
<PAGE>   9
(b)   it shall in no way hold the Amersham Parties responsible or liable for any
      errors or omissions made in financial reporting or administrative support
      to the extent that any such errors or omissions arise, whether directly or
      indirectly as a result of inaccurate, insufficient or out of date
      information having been provided by Biotech after the date of this
      Agreement.

FORCE MAJEURE

7.1 If either party is affected by Force Majeure it shall promptly notify the
other party of the nature and extent of the circumstances in question.

7.2 Notwithstanding any other provision of this Agreement, neither party shall
be deemed to be in breach of this Agreement, or otherwise be liable to the
other, for an delay in performance or other non-performance of any of its
obligations under this Agreement to the extent that the delay or non-performance
is due to any Force Majeure of which it has notified the other party.

7.3 Where a Force Majeure prevents performance of any of their obligations under
this Agreement, the Amersham Parties and Biotech undertake to use reasonable
endeavours to bring the Force Majeure to a close. If Biotech has paid to the
Amersham Parties any amount in respect of the cost of Services that the Amersham
Parties has not provided as a result of Force Majeure and the Amersham Parties
have a policy of insurance in force which enables them to make a claim to cover
any loss they suffer as a result of such Force Majeure, the Amersham Parties
shall make a claim under such policy and account to Biotech for the proceeds of
any such claim to the extent that they represent an amount in respect of the
same costs for which the Amersham Parties has been paid by Biotech as referred
to above.

7.4 If at any time any of the Amersham Parties is affected by Force Majeure in
respect of its obligations under this Agreement with regard to the provision of
the Services or any of them, Biotech shall be entitled to obtain from any other
person the provision of such services as such Amersham Party is unable to
provide, but the Amersham Parties shall, in no way, be held liable or
accountable for any additional cost, loss or liability incurred by Biotech in so
doing.

7.5 Where a Force Majeure event comprises any strike, lock out or similar
industrial action involving some or all of International's employees at the
Site, the Amersham Parties shall be obliged to consult with Biotech regarding
such industrial action and the Amersham Parties shall be obliged to take such
course of action in respect of such strike, lock out or similar industrial
action as Biotech may reasonably request.

DURATION AND TERMINATION

8.1 This Agreement shall come into force on the date hereof and shall continue
in force unless and until terminated in accordance with the following provisions
of this clause 8.
<PAGE>   10
8.2 Subject to clause 8.3 below, at any time on or after the date which is six
months after the date of this Agreement, Biotech may give the Amersham Parties
at least six months' notice in writing to terminate a11 or part of the Services.

8.3 Termination of all or part of the Services provided (i) on or in connection
with Biotech Sites which are granted by lease by the Amersham Parties may not
occur until the date of expiry of the relevant lease and (ii) on or in
connection with the Am Labs and/or Cardiff Sites may not occur until the
termination of the Contract Manufacture Agreement relating to that Site.

8.4.1 Either party shall be entitled forthwith to terminate this Agreement by
written notice to the other if:

(a)   that other party commits any material breach of any of the provisions of
      this Agreement (save for any breach which is caused by the party seeking
      to rely on it) and, in the case of such a breach which is capable of
      remedy, fails to remedy the same within 30 days after receipt of a written
      notice giving reasonable information concerning the breach;

(b)   an encumbrancer takes possession of, or a receiver is appointed over, a
      substantial proportion of the property or assets of that other party;

(c)   that other party makes any voluntary arrangement with its creditors or
      becomes subject to an administration order;

(d)   that other party goes into liquidation (except for the purposes of an
      amalgamation, reconstruction or other reorganisation and in such manner
      that the company resulting from the reorganisation effectively agrees to
      be bound by or to assume the obligations imposed on that other party under
      this Agreement); or

(e)   that other party ceases, or is likely to cease, to carry on business.

8.4.2 In the event of a Controlling Interest in International being acquired by
a third party, Biotech shall be entitled at any time following such event to
terminate this Agreement by 30 days written notice to International (Controlling
Interest meaning (i) the ownership or control (directly or indirectly) of more
than fifty (50) per cent of the voting share capital of International; or (ii)
the ability to direct the casting of more than fifty (50) per cent of the votes
exercisable at general meetings of International on all, or substantially all,
matters; or (iii) the right to appoint or remove directors of International
holding a majority of the voting rights at meetings of the board on all, or
substantially all, matters).

8.5 For the purpose of sub-clause 8.4(a), a breach shall be considered capable
of remedy if the party in breach can comply with the provision in question in
all respects other than as to the time of performance.

8.6 This Agreement may terminate at any time with the written agreement of all
parties.
<PAGE>   11
8.7 International may terminate this Agreement on three months' notice ending On
    or after the sale of any interest in Biotech or any holding company of
    Biotech (whether by way of flotation or trade sale or otherwise) such that
    International ceases to have a direct or indirect interest in at least 50
    per cent. of the voting rights attaching to the ordinary shares of Biotech.

8.8 Any waiver by either party of a breach of any provision of this Agreement
    shall not be considered as a waiver of any subsequent breach of the same or
    any other provision.

8.9 The rights to terminate this Agreement given by this clause 8 shall not
    prejudice any other right or remedy of either party in respect of the breach
    concerned (if any) or any other breach.

EFFECT OF TERMINATION

9.1 Subject (i) to the remainder of this clause 9 and to the obligations of the
parties under clauses 3.4, 4.4, 6.2 and 6.3 which shall continue to have effect
following termination; (ii) to any rights or obligations which have accrued
prior to termination (including, without limitation, any obligation of either
party to pay any other party pursuant to clause 4 for any Services provided);
and (iii) as otherwise expressly provided in this Agreement, upon the
termination of this Agreement for any reason, neither party shall have any
further obligation to the other under this Agreement.

9.2 Following termination of all or any part of the Services provided hereunder
as a result of any notice given by Biotech under clause 8.2, Biotech will
continue to pay to the Amersham Parties amounts in respect of the actual costs
incurred by the Amersham Parties following such termination as a result of
having made available, inter alia, facilities and personnel so as to have been
able to provide the Services so terminated, such amounts to be determined and
paid in accordance with the provisions of Schedule 2.

9.3 Following termination of all or part of the Services provided hereunder as a
result of any notice given by Biotech under clause 8.2 (whether upon termination
of this Agreement or otherwise), the Amersham Parties shall, in consultation
with and taking into account any requests of Biotech, use reasonable endeavours
to reduce the costs incurred by it referred to in clause 9.2 above. Subject as
provided below, Biotech will reimburse the Amersham Parties for such sums as may
be certified by the Amersham Parties as equal to any costs, expenses or other
liabilities incurred by the Amersham Parties as a result of reducing such
costs as aforesaid (including, but not exclusively limited to, redundancy
payments incurred in respect of the termination of the employment of any person
involved in providing such Services, payments made to third parties, relocation
costs, surrender of leases and writing down of assets); provided that in no
event shall Biotech be required to reimburse the Amersham Parties for sums
which, in the aggregate (and taking into account a discount rate equal to LIBOR
to present value for amounts to be paid by Biotech pursuant to clause 9.2),
exceed the amounts which would otherwise have been paid by
<PAGE>   12
Biotech pursuant to clause 9.2 and Schedule 2 in respect of all such terminated
Services. The Amersham Parties will consult with Biotech to determine whether
any such costs, expenses or liabilities may be reduced by Biotech agreeing to
employ any personnel used in providing the relevant Services or otherwise. Any
certificate produced or prepared by the Amersham Parties in accordance with this
clause 9.3 shall be delivered to Biotech on the first Business Day of each of
the four three calendar month periods ending on an International Year End,
together with an invoice in respect of the amount of the costs, expenses and
other liabilities (including VAT, as applicable) incurred in that quarter. Any
amounts payable by Biotech under this clause 9.3 shall be paid within twenty
Business Days of delivery of such invoice.

9.4 The Amersham Parties undertake that if, following the termination of
any Services, they continues to employ any person who had assisted in providing
such Services, all or part of the Amersham Parties' costs in respect of whom are
being charged to Biotech pursuant to this clause 9, they will make available
the relevant proportion of such person's time to assist in the provision of
such of the other Services as that person is capable of assisting with as
continue to be provided to Biotech under this Agreement.

9.5 Without prejudice to the generality of clause 4.1, in the event that Biotech
and/or Pharmacia & Upjohn disagrees with the amount of the actual costs referred
to in clause 9.2 or any amount certified under clause 9.3, the Amersham Parties
shall upon request, supply Biotech and/or Pharmacia & Upjohn with such
information as is reasonably necessary to support the calculations of such
costs. The Amersham Parties shall also permit Biotech to have such access as it
may reasonably request on reasonable notice to the books and records maintained
by the Amersham Parties in connection with the provision of the Services to
enable it to verify such information. The parties shall use all reasonable
endeavours to (in conjunction with their respective accountants) to meet and
discuss the basis of the calculations of each costs but if they fail to reach
agreement within twenty business days of delivery of the statement, then, unless
the parties agree otherwise, the dispute shall be referred to a partner of an
independent internationally recognised firm of chartered accountants agreed upon
by the parties or, failing agreement, to be selected by the president for the
time being of the Institute of Chartered Accountants in England and Wales. The
terms of reference set out in clause 12 shall apply.

NATURE OF AGREEMENT

10.1 The Amersham Parties shall be entitled to perform any of the obligations
undertaken by them and to exercise any of the rights granted to them under this
Agreement with respect to the Services through any other company in the Amersham
Group and any act or omission of any Such company shall for the purposes of this
Agreement be deemed to be the act or omission of International.
<PAGE>   13
10.2 The Amersham Parties shall be entitled to carry out their obligations under
this Agreement with respect to the Services through any agents or
sub-contractors appointed by them in their absolute discretion for that purpose.
Prior to appointing any such agents or sub-contractors, the Amersham Parties
shall whenever reasonably practicable consult with Biotech in connection with
such appointments.

10.3 Except as provided in clauses 10.1 and 10.2, this Agreement is personal to
the parties and neither of them may (without the written consent of the other)
assign, mortgage, charge or dispose of any of its rights hereunder, or
subcontract or otherwise delegate any of its obligations under this Agreement.

10.4 Nothing in this Agreement shall create, or be deemed to create, a
partnership or joint venture between the parties.

10.5 Nothing in this Agreement shall constitute one party as the agent of any
other party.

10.6 Nothing in this Agreement shall make any of the employees of one party the
employees of any other party.

10.7 Any provision of this Agreement may be modified or amended or waived only
by an instrument in writing signed by duly authorised representatives of each of
the parties, in the case of a modification or an amendment, or by the party
against whom the waiver is to be effective, in the case of a waiver.

10.8 Each party acknowledges that, in entering into this Agreement, it does not
do so on the basis of or relying upon any representation, warranty or other
provision except as expressly provided in this Agreement and, accordingly, all
conditions, warranties or other terms implied by statute or common law are
hereby excluded to the fullest extent permitted by law.

10.9 If any of the provisions of this Agreement is or becomes invalid, illegal
or unenforceable, the validity, legality or enforceability of the remaining
provisions shall not in any way be affected or impaired. If any provision of
this Agreement, or the application thereof to any person or entity or any
circumstance, is invalid or unenforceable, the parties shall make suitable and
equitable provision therefor in order to carry out, so far as may be valid and
enforceable, the intent and purpose of such invalid or unenforceable provision.

10.10 This Agreement sets out the entire agreement and understanding between the
parties with respect to the subject matter hereof. This Agreement replaces the
agreement between International and Amersham Life Science UK Ltd, dated 2 June
1997 which shall cease and determine with effect that the execution of this
Agreement, save in respect of any rights and obligations which have accrued
prior thereto. It is agreed that:

(a)   neither party has entered into this Agreement in reliance upon any
      representation, warranty or undertaking of the other party which is not
      expressly set out or referred to in this Agreement; and
<PAGE>   14
(b)   this clause shall not exclude any liability for fraudulent
      misrepresentation.

NOTICES

11.1 All notices, requests, demands, or other communications made pursuant to
this Agreement shall be made by telefax, overnight express courier or hand
delivered against receipt to the applicable Party as indicated below:

(a)   if to International, to:

      Fax No:       01494 542242
      Address:      Amersham Place
                    Little Chalfont
                    Buckinghamshire HP7 9NA

      For the attention of: G.F.B. Kerr (Company Secretary)

(b)   if to Holdings, to:

      Fax No:       847-593-6339
      Address:      Amersham Holdings, Inc.
                    2636 S. Clearbrook Drive
                    Arlington Heights, IL 60005

      For the attention of: Wayne Fairbrother (Secretary)

(c)   if to Biotech, to:

      Fax No:       01494 542242
      Address:      Amersham Place
                    Little Chalfont
                    Buckinghamshire
                    HP7 9NA

      For the attention of: JA Cooper (Company Secretary)

      With a copy to Pharmacia & Upjohn at:

      Fax No:       01753  744008
      Address:      67 Alma Road
                    Windsor
                    Berkshire
                    England SL4 3HD

      For the attention of: Executive Vice President, General Counsel and
      Secretary

11.2 Communications shall be deemed to have been made upon receipt if by
telefax, overnight express courier or by hand delivery, except that a telefax,
that is received on a day which is not a Business Day or after Business Hours
shall be deemed to have been made at the opening of business on the first
following day that is a Business Day.

<PAGE>   15
TERMS OF REFERENCE FOR DISPUTES

12.  In the event of a dispute arising under clause 5.6 or 9.5, the following
terms of reference shall apply:

(a)  the parties shall each use all reasonable endeavours to assist the firm to
     resolve the matter and to ensure that the independent firm has such access
     to all relevant working papers of each party as are reasonably necessary
     for the purpose;

(b)  any such independent firm shall act as an expert (and not as an arbitrator)
     in making any such determination which shall be binding on the parties;

(c)  the expenses of any such determination by an independent firm shall be
     borne between the parties in such proportions as the firm shall in its
     discretion determine.

ARBITRATION AND GOVERNING LAW

13.1 In the event of any dispute between the Amersham Parties and Biotech
arising in connection with this Agreement, the parties shall use all reasonable
endeavours to resolve the matter on an amicable basis. If one party serves
formal written notice on the other that a material dispute of such a
description has arisen and the parties are unable to resolve the dispute within
a period of thirty days from the service of such notice, then the dispute shall
be referred to the respective chief executive officers of International,
Pharmacia & Upjohn and Biotech with a view to the dispute being resolved as
early as possible.

13.2 If any dispute is unresolved by the chief executive officers within a
period of thirty days from the date such referral of such dispute to them, such
dispute may after the expiry of such period of thirty days be referred by either
party to and finally settled by arbitration under the Rules of the London Court
of International Arbitration by one or more arbitrators appointed in accordance
with those Rules. The place of arbitration shall be London. The language of
arbitration proceedings shall be English.

13.3 This Agreement shall be governed by and construed in all respects in
accordance with the laws of England.

AS WITNESS this Agreement has been signed by the duly authorised
representatives of the Parties the day and year first before written.
<PAGE>   16
                                   SCHEDULE 1

                PART A: SERVICES TO BE PROVIDED BY INTERNATIONAL

<TABLE>
<CAPTION>
1      GROUP LOGISTICS                                                                     ESTIMATED
                                                                                              ANNUAL
                                                                                                COST
<S>                                                                     <C>
1.1    Distribution other than Warehouse, Freight Transport and           (pound sterling) 1,193,000
       GLD Packaging Design

       NATURE

       Management of logistics, stores, freight administration, pack
       design and ensuring compliance with Customs and Excise
       regulations.

       BASIS OF THE CHARGE

       In proportion to the estimated number of staff supporting
       this business

1.2    WAREHOUSE                                                            (pound sterling) 931,000

       NATURE

       The warehouse provides a picking, packaging and a
       shipment consolidation service for all products manufactured
       by Amersham International plc.

       BASIS OF CHARGE

       2.0.1   Warehouse - This is charged in proportion to the
       estimated number of staff supporting this business

       2.0.2   Packaging - Costs are either:

       -       Specific to a business with separate analysis codes (eg
               100% LS - dry ice and expanded polystyrene);

               or

       -       If shared (where the packaging is used by more than
               one business) on the basis of the number of line items
               by business.

1.3    FREIGHT                                                            (pound sterling) 2,240,000

</TABLE>
<PAGE>   17

<TABLE>
<S>                                                                     <C>
     NATURE

     This covers the cost of distribution from Amersham
     International plc to any of its subsidiaries, distributors or
     customers in the United Kingdom. The costs of final delivery
     to the customer are borne locally. Charges also include the
     cost of manufacturing freight (i.e. for moving products other
     than to customers, e.g. moving intermediates and stocks
     between Cardiff and Amersham).

     BASIS OF THE CHARGE

     The distribution model calculates the actual cost of freight by
     business. Where this differs from actual costs the difference
     is allocated pro rata.

     Cost of third party freight forwarders is allocated across
     each of the businesses.

1.4  TRANSPORT                                                               (pound sterling)168,000

     NATURE

     This is the cost of distribution to customers and internal
     transport between different sites of Amersham International plc.

     BASIS OF THE CHARGE

     1.4.1     To customers - based on package weight distributed
     by this business.

     1.4.2     Internal - based on the estimated number of staff
     supporting this business.

1.5  GLD Packaging Design                                                     (pound sterling)40,000

     NATURE

     Design work associated with packaging (and chargeable to cost
     of sales) which includes vials, CDS and lead pots.

     BASIS OF CHARGE

     Based on actual hours worked by project at a standard recovery
     rate.

2    PURCHASING

2.1  Purchasing other than the costs of reprographics                        (pound sterling)418,000

     NATURE

     Management of suppliers, purchasing, orders and materials.
</TABLE>

<PAGE>   18
          BASIS OF THE CHARGE

          In proportion to the number of staff supporting
          this business.

     2.2  REPROGRAPHICS                                  (pound sterling) 46,000

          NATURE

          Printing service for all departments of Amersham
          International plc at sites at Amersham, Cardiff
          and all subsidiaries. The service is provided by
          either Amersham International plc, externally or a
          combination of both.

          BASIS OF CHARGE

          Charge per copy equivalent to such costs of a
          third party supplier.

      3.  SCIENCE ADVISER/IDEA LINK                    (pound sterling) 107,000

          NATURE

          Provision of general scientific advice and
          management of the Company suggestion scheme.

          Basis of Charge

          Management of Amersham International plc
          judgement.

      4.  TECHNICAL SERVICES ACCOUNTING                  (pound sterling) 49,000

          NATURE

          The unit undertakes accounting for the Technical
          Services Group which includes Engineering, Group
          Logistics, Safety, Patents and Quality Assurance.

          Basis of the Charge

          Management of Amersham International plc
          judgement.

      5.  INSURANCE

<PAGE>   19
     NATURE

     Annual premiums are placed for all insurances though a single broker
(Willis Coroon) and the process is managed by Secretariat. The premiums are
charged to Secretariat which recharge them on appropriate basis to the relevant
cost centres.

     BASES OF CHARGE

     Site Liability          - Charge based on asset     (pound sterling) 32,000
                               values within site

     Material Damage         - Charge based on asset    (pound sterling) 143,000
                               values within site

     Product Liability       - Charge apportioned       (pound sterling) 268,000
                               between businesses in
                               proportion to turnover

     Business Interruption   - Charge apportioned       (pound sterling) 180,000
                               between businesses in
                               proportion to turnover

     Motor                   - In proportion to the      (pound sterling) 53,000
                               number of company car
                               drivers employed by
                               the business

6.   HUMAN RESOURCES                                    (pound sterling) 804,000

     NATURE

     The provision of personnel services including
     training, recruitment, compensation and benefits
     systems.

     BASIS OF CHARGE

     Charged according to estimates made by each
     Human Resources manager of the amount of
     their services provided to the business.

7.   TELEPHONE CHARGES AT AMERSHAM PLACE                 (pound sterling) 58,000
<PAGE>   20

     NATURE

     Telephone charges.

     Basis of the Charge
     In proportion to the estimated use by the business based
     upon past usage as shown by call logging records.

8.   IT LEASING EQUIPMENT                               (pound sterling) 129,000

     NATURE

     Some existing and all future computing equipment will be
     the subject of leases managed by Group Information
     Systems.

     BASIS OF THE CHARGE

     On the basis of the personal computer equipment expected
     to be leased by the business in the year.

9.   DESKTOP MAINTENANCE                                (pound sterling)  94,000

     NATURE

     All personal computer equipment is maintained by external
     contractors under agreements established and managed by
     Group Information Systems.

     BASIS OF THE CHARGE

     The costs of maintenance by external contractors is charged
     according to the number of personal computers used by the
     business.

10.  CENTRAL FINANCIAL SERVICES                         (pound sterling) 393,000

     NATURE

     The unit provides payroll and Cash Office services and
     maintains the Accounts Payable, Accounts Receivable and
     General Ledgers.

     BASIS OF THE CHARGE

     Costs are apportioned to each business on the basis of
     estimated use of each Service

<PAGE>   21
11.  HEAD OFFICE BUILDING                               (pound sterling) 609,000

     NATURE

     Costs of running the Head Office building.

     BASIS OF THE CHARGE

     Charged in proportion to the occupancy of
     the building.

12.  GROUP INFORMATION SERVICES

     NATURE

     The group provides services covering the operation
     and development of computer systems including the
     provision of network services.

     BASIS OF THE CHARGE

     In proportion to the amount of sales of the
     business compared to sales of the Amersham
     International Group:

     GIS Management     IT Director costs               (pound sterling) 151,000

     GIS Operations     Applications development        (pound sterling) 520,000

     GIS Projects       Major development projects      (pound sterling) 890,000

     in proportion to the number of staff employed      (pound sterling) 638,000
     in the business; and

     Network Services   IT network costs, staff costs
                        plus external services

     In proportion to the estimated use of each system
     by the business:

     Computer Services  Operation of mainframe        (pound sterling) 1,092,000
                        computers and provision of
                        personal computer services
                        and user support

     In proportion to the amount of sales of the
     business compared to sales of the Amersham
     International Group:

     Commercial GRS Operation of Group Regional         (pound sterling) 437,000
     System and provision of business systems support.

13.  TREASURY ARRANGEMENTS

<PAGE>   22
Nature

International will provide currency management services, including foreign
exchange, in accordance with existing International policies.

BASIS OF THE CHARGE

Cover will be provided on an arms length Reuters rate.

NATURE

International will lend to and borrow for Biotech in accordance with existing
practice.

BASIS OF THE CHARGE

Borrowings will be on an arms-length basis.

NATURE

International will settle intra-group trading and other debts in accordance
with existing practice.
<PAGE>   23
                  PART B: SERVICES TO BE PROVIDED BY AMERSHAM
                                    HOLDINGS, INC.

                                                           ESTIMATED ANNUAL COST

                                                                  ($000 omitted)

1.   REGULATORY AND ENVIRONMENTAL REGULATORY                              US$506
     AFFAIRS

     NATURE: Management of Regulatory Affairs and
     health, safety, environmental regulatory
     monitoring and compliance, and company library.

     BASIS OF CHARGE:

<TABLE>
<CAPTION>
                       TOTAL   % ALLOCATED TO   ALLOCATED
DEPARTMENT            BUDGET     LIFE SCIENCE      AMOUNT   BASIS OF ALLOCATION
<S>                   <C>      <C>             <C>         <C>
Regulatory Affairs       431             18.0         78      Estimated efforts

Environ Reg Affairs      948             42.0        398      Estimated efforts

Library                   60             50.0         30      Estimated efforts

                                       Total:        506
</TABLE>

2.   FACILITIES AND CORPORATE PURCHASING                                  US$672

     NATURE: Management and expenses to run and
     maintain the South Arlington Heights facility
     including corporate purchasing.

     BASIS OF CHARGE:

<TABLE>
<CAPTION>
                       TOTAL   % ALLOCATED TO   ALLOCATED
DEPARTMENT            BUDGET     LIFE SCIENCE      AMOUNT   BASIS OF ALLOCATION
<S>                   <C>      <C>             <C>         <C>
Corporate Purchasing     216             36.1          8      Estimated efforts

Engineering/           1,220             48.7        594               Building
Maintenance

                                       Total:        672               Occupancy
</TABLE>

3.   FINANCE AND ACCOUNTING                                             US$1,127

     NATURE: Corporate functions that provide
     financial and accounting services for
     all through business and Shared Services.

     BASIS OF CHARGE:

<TABLE>
<CAPTION>
                       TOTAL   % ALLOCATED TO   ALLOCATED
DEPARTMENT            BUDGET     LIFE SCIENCE      AMOUNT   BASIS OF ALLOCATION
<S>                   <C>      <C>              <C>         <C>
</TABLE>
<PAGE>   24
<TABLE>
<S>                       <C>       <C>        <C>      <C>
Controller                 334        30.0      100      Estimated efforts
General Accounting         387        41.0      159      Estimated efforts
Accounts Payable           229        41.0       94      Invoices processed
Payroll                    199        32.0       64      Headcount
Credit Management          434        45.0      195      Estimated efforts
Tax                        229        48.0      110      Estimated efforts
Cost Accounting            171         6.0       10      Salary percentages
Financial Management       266        45.0      120      Estimated efforts
Fleet Administration       244        24.0       59      Vehicles/Est efforts
LS Customer Collections    217       100.0      217      LS Specific

                                    Total:    1,127
</TABLE>

4.   HOLDINGS ADMINISTRATION                                              US$220

     NATURE: Expenses of the Holdings
     function including Board of
     Directors expenses and Shared
     Services expenses and Senior
     Management incentive bonus plan.

     BASIS OF CHARGE:

<TABLE>
<CAPTION>
                  TOTAL   % ALLOCATED TO   ALLOCATED
DEPARTMENT        BUDGET   LIFE SCIENCE     AMOUNT     BASIS OF ALLOCATION
<S>                <C>       <C>             <C>       <C>
Holdings            550       40.0            220       Estimated efforts
Administration
</TABLE>

5.   INFORMATION SERVICES                                               US$1,884

     NATURE:   Management and expenses
     of the hardware, software and personnel
     of the various information functions
     for all business, mainframe computer
     systems, pc network, and
     telecommunications.

     BASIS OF CHARGE:

<TABLE>
<CAPTION>
                  TOTAL   % ALLOCATED TO   ALLOCATED
DEPARTMENT        BUDGET   LIFE SCIENCE     AMOUNT     BASIS OF ALLOCATION
<S>                <C>       <C>             <C>       <C>
Management          281       48.0            135       Estimated efforts
Bus System Develop  805       50.0            403       Estimated efforts
</TABLE>

<PAGE>   25
<TABLE>
<S>                           <S>           <C>             <C>                 <C>
Info Tech Group               2,561          48.7           1,247               Estimated efforts
LS Support                       99         100.0              99               Life Science Specific
                                            Total:          1,884

</TABLE>

6.   HUMAN RESOURCES                                        US$395

     NATURE: Management of Human Resources
     functions and employee benefits and training.

     BASIS OF CHARGE:

<TABLE>
<CAPTION>
DEPARTMENT                     TOTAL         % ALLOCATED TO    ALLOCATED            BASIS OF ALLOCATION
                              BUDGET          LIFE SCIENCE      AMOUNT
<S>                           <S>           <C>                <C>                 <C>
Administration                 253            26.0                66                  Headcount

Operations                     567            26.0               147                  Headcount

Benefits & Comp                554            26.0               144                  Headcount
Admin

Training and                   461            26.0               120                  Headcount
Develop

Employee Relations             132            26.0                40                  Headcount

Benefits (Net of              -468            26.0              -122                  Headcount
charges to dept)

                                              Total:             395
</TABLE>

<PAGE>   26

7.  HOLDINGS SERVICES                                                     US$417

    NATURE: Management of facility
    services for South Arlington
    Heights including security and
    housekeeping.

    BASIS OF CHARGE:

<TABLE>
<CAPTION>
                                             TOTAL   % ALLOCATED TO   ALLOCATED
DEPARTMENT                                  BUDGET     LIFE SCIENCE      AMOUNT   BASIS OF ALLOCATION
<S>                                         <C>      <C>              <C>         <C>
Security & Housekeeping                        617             48.7         300     Building occupancy
Facility Services Management                   361             26.0          94              Headcount
Training                                        43             54.0          23              Headcount
                                                             Total:         417
</TABLE>

8.  DISTRIBUTION                                                        US$1,179

    NATURE:  Picking, packing and
    transportation of all goods from
    South Arlington Heights. Receiving
    for all goods into South Arlington
    Heights.

    BASIS OF CHARGE:

<TABLE>
<CAPTION>
                                               TOTAL   % ALLOCATED TO   ALLOCATED
DEPARTMENT                                    BUDGET     LIFE SCIENCE      AMOUNT   BASIS OF ALLOCATION
<S>                                           <C>      <C>              <C>         <C>
Traffic                                        1,453             77.0       1,119     Estimated efforts
Receiving                                        224             27.0          60     Estimated efforts
                                                               Total:       1,179
</TABLE>

<PAGE>   27
9.   MISCELLANEOUS                                                    US$96

     NATURE: Non specific miscellaneous expenses
     including bank fees, credit card fees, other income
     and expense items.

     BASIS OF CHARGE:

<TABLE>
<CAPTION>
DEPARTMENT          TOTAL          % ALLOCATED TO      ALLOCATED      BASIS OF ALLOCATION
                   BUDGET            LIFE SCIENCE         AMOUNT
<S>               <C>              <C>                 <C>            <C>
Miscellaneous         300                    31.9              %                 Estimate
Expenses

ESTIMATED TOTAL SHARED SERVICES 97/98                                            US$6,496
(1 APRIL 97 - 31 MARCH 98)
</TABLE>
<PAGE>   28
                                   SCHEDULE 2

                           SHARED SERVICE TERMINATION

1.  The charges to be paid by Biotech in respect of the costs of any Services
    following termination of the provision of such Services shall be calculated
    by reference to the actual charges made in respect of the relevant Services
    that have been terminated in the twelve months prior to such termination and
    using the rates and bases set out in Schedule 1 (as revised from time to
    time) and in accordance with the principles referred to in clause 5.1. The
    provisions of the remainder of clause 5 shall to the extent applicable
    continue to apply to the manner and timing of any payment. The proportion of
    the charges payable by Biotech in the period following such termination
    shall be reduced in accordance with paragraph 2 below. If, as a result of
    any action taken by the Amersham Parties as referred to in clause 9.3, the
    costs of the Amersham Parties referred to above are reduced beneath the
    actual charges made in the twelve month period referred to then the amounts
    payable by Biotech shall be reduced accordingly (without prejudice to any
    payment obligation arising under clause 9.3)

<TABLE>
<CAPTION>

2.                                         NUMBER OF MONTHS AFTER TERMINATION EFFECTIVE

                                           0-6 MTHS    7-12 MTHS   13-18 MTHS   EACH MONTH
                                                                                 FROM AND
                                                                                INCLUDING
                                                                                19 MONTHS

<S>                                        <C>          <C>        <C>          <C>
Proportion of ongoing service              100%         80%        50%          0%
charge to be paid
</TABLE>
<PAGE>   29
SIGNED by Kevin P. Kissane           )
for and on behalf of                 )
AMERSHAM INTERNATIONAL               )       /s/ Kevin P. Kissane
PLC in the presence of: JAMES WOOD,  )
   Freshfields, 65 Fleet St, London  )

SIGNED by Kevin P. Kissane           )
for and on behalf of                 )
AMERSHAM PHARMACIA                   )       /s/ Kevin P. Kissane
BIOTECH LIMITED                      )
in the presence of: JAMES WOOD,      )
 Freshfields, 65 Fleet St, London    )

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}]]